Many neurodegenerative diseases are characterized by the conformational change of self-proteins into amyloidogenic, pathological conformers, which share structural properties such as high ?-sheet content and resistance to degradation. Alzheimer's disease (AD) is the most common of the neurodegenerative protein conformational disorders, which include diffuse Lewy body disease (DLBD), Parkinson's disease (PD), prion diseases, and frontotemporal lobar degeneration (FTLD). The most toxic conformers are the oligomeric forms. None of the conformational diseases has an effective therapy;however, immunomodulation has shown great promise for both AD and prion diseases. Major problems with this approach include: the potential of toxicity from encephalitis (related to excessive cell mediated immunity), the immunological targeting of both the normal and abnormal A?, the resistance of vascular amyloid to clearance, as well as tau related pathology not being specifically addressed. The central hypothesis of this proposal is that each of these limitations can be overcome by specific targeting of abnormal oligomer conformation and development of novel methods to prevent oligomer mediated toxicity. Our novel active immunomodulation approach uses a polymerized British amyloidosis (pABri) related peptide in a predominantly ?-sheet, oligomeric form. We hypothesized that through """"""""conformational mimicry"""""""" the polymerized ABri peptide could induce a conformation selective immune response that will recognize both A? and conformationally abnormal tau. This hypothesis is supported by preliminary data in an APP/PS1 AD mouse model. Such an immunostimulatory approach should have a reduced risk of inducing auto-immune complications as it is more specific to a pathological conformer and the immunogen has no sequence homology to any known mammalian protein/peptide. We also present preliminary data that short term treatment with monoclonal 6D11, an anti-PrP antibody, reverses behavioral deficits in an AD model APP/PS1 Tg mice. This antibody blocks the binding of A? oligomers to PrPC. We hypothesize that blocking the binding of A? oligomers and PrPC is a novel therapeutic strategy for AD. These complementary approaches will aim to both increase clearance of A? oligomers and specifically block their toxicity.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Corriveau, Roderick A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Schools of Medicine
New York
United States
Zip Code
Pomara, Nunzio; Bruno, Davide; Osorio, Ricardo S et al. (2016) State-dependent alterations in cerebrospinal fluid Aβ42 levels in cognitively intact elderly with late-life major depression. Neuroreport 27:1068-71
Chu, Jin; Wisniewski, Thomas; Praticò, Domenico (2016) GATA1-mediated transcriptional regulation of the γ-secretase activating protein increases Aβ formation in Down syndrome. Ann Neurol 79:138-43
Wisniewski, Thomas; Drummond, Eleanor (2016) Developing therapeutic vaccines against Alzheimer's disease. Expert Rev Vaccines 15:401-15
Hickman, Richard A; Faustin, Arline; Wisniewski, Thomas (2016) Alzheimer Disease and Its Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Need for Therapeutics. Neurol Clin 34:941-953
Teoh, Chai Lean; Su, Dongdong; Sahu, Srikanta et al. (2015) Chemical Fluorescent Probe for Detection of Aβ Oligomers. J Am Chem Soc 137:13503-9
Goñi, Fernando; Mathiason, Candace K; Yim, Lucia et al. (2015) Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease. Vaccine 33:726-33
Wisniewski, Thomas; Goñi, Fernando (2015) Immunotherapeutic approaches for Alzheimer's disease. Neuron 85:1162-76
Ji, Yong; Shi, Zhihong; Zhang, Ying et al. (2015) Prevalence of dementia and main subtypes in rural northern China. Dement Geriatr Cogn Disord 39:294-302
Sabharwal, Priyanka; Wisniewski, Thomas (2014) Novel immunological approaches for the treatment of Alzheimer's disease. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi 14:139-151
Scholtzova, Henrieta; Chianchiano, Peter; Pan, Jason et al. (2014) Amyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation. Acta Neuropathol Commun 2:101

Showing the most recent 10 out of 41 publications